Latest

2 stories

Hide weekly roundups

Thursday, September 10

The company began production of oxypurinol drug substance and tablets to support its XRX-OXY-102 trial and a future FDA marketing application.

SEC filing

Chairman Anthony Giovinazzo left the board on July 31 while independent director Depesh Narotam joined effective July 27, 2026.

SEC filing (2)